share_log

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Institutional Investors Lost 28% Over the Past Week but Have Profited From Longer-term Gains

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Institutional Investors Lost 28% Over the Past Week but Have Profited From Longer-term Gains

Heron Therapeutics, Inc.(納斯達克:HRTX)的機構投資者在過去一週損失了28%,但從長期收益中獲益。
Simply Wall St ·  11/13 18:04

Key Insights

主要見解

  • Institutions' substantial holdings in Heron Therapeutics implies that they have significant influence over the company's share price
  • A total of 8 investors have a majority stake in the company with 50% ownership
  • Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company
  • 機構在heron therapeutics的大量持股意味着他們對公司股價有重要影響力
  • 共有8家投資者擁有該公司的50%所有權。
  • 通過分析師預測數據和所有權研究,您可以更好地評估公司未來的業績。

Every investor in Heron Therapeutics, Inc. (NASDAQ:HRTX) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 64% to be precise, is institutions. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

納斯達克:HRTX)的每位投資者都應該意識到最強大的股東群體。持有公司股份最多的群體,具體來說約佔64%,爲機構。換句話說,該群體將從他們對公司的投資中獲得最多(或者損失最多)

Institutional investors endured the highest losses after the company's market cap fell by US$74m last week. Still, the 137% one-year gains may have helped mitigate their overall losses. We would assume however, that they would be on the lookout for weakness in the future.

上週該公司市值下降了7400萬美元后,機構投資者遭受了最嚴重的損失。不過,一年內漲幅達137%,可能有助於緩解他們的總體損失。然而我們會假設,他們將會對未來的弱點保持警惕。

Let's take a closer look to see what the different types of shareholders can tell us about Heron Therapeutics.

讓我們仔細觀察一下,看看不同類型的股東能告訴我們關於heron therapeutics的什麼信息。

big
NasdaqCM:HRTX Ownership Breakdown November 13th 2024
NasdaqCM:HRTX 2024年11月13日的所有權分佈

What Does The Institutional Ownership Tell Us About Heron Therapeutics?

機構持股告訴我們關於heron therapeutics的什麼信息?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。

As you can see, institutional investors have a fair amount of stake in Heron Therapeutics. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Heron Therapeutics' earnings history below. Of course, the future is what really matters.

正如您所看到的,機構投資者在heron therapeutics擁有相當大的股份。這可能表明公司在投資社區具有一定可信度。然而,最好不要過分依賴機構投資者所帶來的所謂驗證。他們有時也會判斷錯誤。如果多家機構同時改變對一隻股票的觀點,您可能會看到股價快速下跌。因此,值得查看下面heron therapeutics的盈利歷史。當然,未來才是真正重要的。

big
NasdaqCM:HRTX Earnings and Revenue Growth November 13th 2024
納斯達克資本市場:heron therapeutics 2024年11月13日的盈利和營收增長

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Our data indicates that hedge funds own 23% of Heron Therapeutics. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Our data shows that Rubric Capital Management LP is the largest shareholder with 18% of shares outstanding. The second and third largest shareholders are The Vanguard Group, Inc. and BlackRock, Inc., with an equal amount of shares to their name at 5.7%.

投資者應注意,機構實際上擁有公司超過一半的股份,因此他們可以共同行使重要權力。我們的數據顯示,對於heron therapeutics,對沖基金擁有23%的股份。這引起了我的注意,因爲對沖基金有時會試圖影響管理層,或者帶來能夠爲股東創造近期價值的變化。我們的數據顯示,Rubric Capital Management LP是最大的股東,持有18%的流通股。第二和第三大股東是The Vanguard Group,Inc.和BlackRock,Inc.,他們的持股比例相同,均爲5.7%。

We did some more digging and found that 8 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們對Brookfield Infrastructure有了更深入的了解,發現前8位股東佔持股比例的約50%,這意味着除了大股東外還有少數小股東,從而在一定程度上平衡了彼此的利益。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

儘管研究公司的機構持股可以增加您的研究價值,但研究分析師的建議也是一個好習慣,以更深入地了解股票的預期表現。有相當數量的分析師關注該股,因此了解他們對未來的總體觀點可能很有用。

Insider Ownership Of Heron Therapeutics

Heron Therapeutics的內部持股

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並在不同的司法管轄區之間有所不同。我們的數據反映了個人內部人員,至少包括董事會成員。管理層最終向董事會負責。然而,經理們成爲執行董事會成員並不罕見,尤其是如果他們是創始人或首席執行官。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。

Our most recent data indicates that insiders own some shares in Heron Therapeutics, Inc.. In their own names, insiders own US$2.8m worth of stock in the US$279m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

我們最近的數據顯示,內部持有人擁有heron therapeutics股票的一部分。在他們自己的名字下,內部持有人擁有價值280萬美元的美國27900萬美元公司的股票。這至少顯示了一些一致性。您可以單擊此處查看這些內部持有人是否一直在買入或賣出。

General Public Ownership

一般大衆所有權

The general public, who are usually individual investors, hold a 13% stake in Heron Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

一般公衆,通常是個人投資者,在heron therapeutics持有13%的股份。儘管這個群體不能必然左右公司的運行,但肯定會對公司的運營產生實際影響。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Heron Therapeutics has 3 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.

儘管考慮到擁有公司的不同群體是非常值得的,但還有其他更重要的因素。例如,風險-heron therapeutics有3個警示標誌(還有一個讓我們有點不舒服),我們認爲你應該知道。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論